期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 623, 期 1-3, 页码 89-95出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2009.09.010
关键词
Angiogenesis; HMGB1; HRG; Heparin
资金
- Japan Foundation of Cardiovascular Research
- Japan Society for the Promotion of Science (JSPS) [21390071, 21659141, 21590594]
- Mitsui Sumitomo Insurance Welfare Foundation
- Grants-in-Aid for Scientific Research [21590594] Funding Source: KAKEN
Histidine-rich glycoprotein (HRG) is a heparin-binding glycoprotein present in plasma at 100 mu g/ml. A recent Study revealed that HRG Suppressed heparin-dependent basic fibroblast growth factor (bFGF)-induced angiogenesis. Additionally, we reported that hi.-h mobility group box 1 (HMGB1) in complex with heparin induces angiogenesis; therefore, we examined the effect of HRG oil heparin-dependent HMGB1-induced angiogenesis in the present study. HRG completely inhibited angiogenesis induced by HMGB1 in complex with heparin. HRG inhibited the diffusion of a complex of HMGB1 with heparin front matrigel into surrounding tissue. HRG also competed with HMGB1 for heparin binding in vitro. Moreover, HRG inhibited heparin-dependent vascular endothelial growth factor-A(165) (VEGF-A(165))-induced angiogenesis. These results Strongly suggested that HRG might be an inhibitor of angiogenesis induced by growth factors with heparin binding activity and that HRG may be a potential drug for angiogenic diseases, including tumor growth. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据